|
1
|
Howlader N, Noone AM, Krapcho M, Garshell
J, Neyman N, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,
et al: National Cancer Institute: SEER Cancer Statistics Review,
1975–2010. http://seer.cancer.gov/csr/1975_2010/.
Accessed June 14, 2013
|
|
2
|
Kaur S, Venktaraman G, Jain M, Senapati S,
Garg PK and Batra SK: Recent trends in antibody-based oncologic
imaging. Cancer Lett. 315:97–111. 2012. View Article : Google Scholar :
|
|
3
|
Verma S, Miles D, Gianni L, Krop IE,
Welslau M, Baselga J, Pegram M, Oh DY, Diéras V, Guardino E, et al;
EMILIA Study Group. Trastuzumab emtansine for HER2-positive
advanced breast cancer. N Engl J Med. 367:1783–1791. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ricart AD and Tolcher AW: Technology
insight: Cytotoxic drug immunoconjugates for cancer therapy. Nat
Clin Pract Oncol. 4:245–255. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Rickles FR, Levine M and Edwards RL:
Hemostatic alterations in cancer patients. Cancer Metastasis Rev.
11:237–248. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Stein PD, Beemath A, Meyers FA, Skaf E,
Sanchez J and Olson RE: Incidence of venous thromboembolism in
patients hospitalized with cancer. Am J Med. 119:60–68. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Matsumura Y: Cancer stromal targeting
(CAST) therapy. Adv Drug Deliv Rev. 64:710–719. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Callander NS, Varki N and Rao LV:
Immunohistochemical identification of tissue factor in solid
tumors. Cancer. 70:1194–1201. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kasthuri RS, Taubman MB and Mackman N:
Role of tissue factor in cancer. J Clin Oncol. 27:4834–4838. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
van den Berg YW, Osanto S, Reitsma PH and
Versteeg HH: The relationship between tissue factor and cancer
progression: Insights from bench and bedside. Blood. 119:924–932.
2012. View Article : Google Scholar
|
|
11
|
Contrino J, Hair G, Kreutzer DL and
Rickles FR: In situ detection of tissue factor in vascular
endothelial cells: Correlation with the malignant phenotype of
human breast disease. Nat Med. 2:209–215. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Vrana JA, Stang MT, Grande JP and Getz MJ:
Expression of tissue factor in tumor stroma correlates with
progression to invasive human breast cancer: Paracrine regulation
by carcinoma cell-derived members of the transforming growth factor
beta family. Cancer Res. 56:5063–5070. 1996.PubMed/NCBI
|
|
13
|
Ueno T, Toi M, Koike M, Nakamura S and
Tominaga T: Tissue factor expression in breast cancer tissues: Its
correlation with prognosis and plasma concentration. Br J Cancer.
83:164–170. 2000.PubMed/NCBI
|
|
14
|
Versteeg HH and Ruf W: Emerging insights
in tissue factor-dependent signaling events. Semin Thromb Hemost.
32:24–32. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Langer F and Bokemeyer C: Crosstalk
between cancer and haemostasis. Implications for cancer biology and
cancer-associated thrombosis with focus on tissue factor.
Hamostaseologie. 32:95–104. 2012. View Article : Google Scholar
|
|
16
|
Khorana AA, Ahrendt SA, Ryan CK, Francis
CW, Hruban RH, Hu YC, Hostetter G, Harvey J and Taubman MB: Tissue
factor expression, angiogenesis, and thrombosis in pancreatic
cancer. Clin Cancer Res. 13:2870–2875. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Milsom CC, Yu JL, Mackman N, Micallef J,
Anderson GM, Guha A and Rak JW: Tissue factor regulation by
epidermal growth factor receptor and epithelial-to-mesenchymal
transitions: Effect on tumor initiation and angiogenesis. Cancer
Res. 68:10068–10076. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hjortoe GM, Petersen LC, Albrektsen T,
Sorensen BB, Norby PL, Mandal SK, Pendurthi UR and Rao LV: Tissue
factor-factor VIIa-specific up-regulation of IL-8 expression in
MDA-MB-231 cells is mediated by PAR-2 and results in increased cell
migration. Blood. 103:3029–3037. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Regina S, Valentin JB, Lachot S, Lemarié
E, Rollin J and Gruel Y: Increased tissue factor expression is
associated with reduced survival in non-small cell lung cancer and
with mutations of TP53 and PTEN. Clin Chem. 55:1834–1842. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yamashita H, Kitayama J, Ishikawa M and
Nagawa H: Tissue factor expression is a clinical indicator of
lymphatic metastasis and poor prognosis in gastric cancer with
intestinal phenotype. J Surg Oncol. 95:324–331. 2007. View Article : Google Scholar
|
|
21
|
Kaido T, Oe H, Yoshikawa A, Mori A, Arii S
and Imamura M: Tissue factor is a useful prognostic factor of
recurrence in hepatocellular carcinoma in 5-year survivors.
Hepatogastroenterology. 52:1383–1387. 2005.PubMed/NCBI
|
|
22
|
Nitori N, Ino Y, Nakanishi Y, Yamada T,
Honda K, Yanagihara K, Kosuge T, Kanai Y, Kitajima M and Hirohashi
S: Prognostic significance of tissue factor in pancreatic ductal
adenocarcinoma. Clin Cancer Res. 11:2531–2539. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sato R, Obonai T, Tsumura R, Tsumoto K,
Koga Y, Yasunaga M and Matsumura Y: Preparation and
characterization of anti-tissue factor single-chain variable
fragment antibody for cancer diagnosis. Cancer Sci. 105:1631–1637.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Koga Y, Manabe S, Aihara Y, Sato R,
Tsumura R, Iwafuji H, Furuya F, Fuchigami H, Fujiwara Y, Hisada Y,
et al: Antitumor effect of antitissue factor antibody-MMAE
conjugate in human pancreatic tumor xenografts. Int J Cancer. Feb
20–2015.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hong H, Zhang Y, Nayak TR, Engle JW, Wong
HC, Liu B, Barnhart TE and Cai W: Immuno-PET of tissue factor in
pancreatic cancer. J Nucl Med. 53:1748–1754. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Versteeg HH, Schaffner F, Kerver M,
Petersen HH, Ahamed J, Felding-Habermann B, Takada Y, Mueller BM
and Ruf W: Inhibition of tissue factor signaling suppresses tumor
growth. Blood. 111:190–199. 2008. View Article : Google Scholar
|
|
27
|
Harter PN, Dützmann S, Drott U, Zachskorn
C, Hattingen E, Capper D, Gessler F, Senft C, Seifert V, Plate KH,
et al: Anti-tissue factor (TF9-10H10) treatment reduces tumor cell
invasiveness in a novel migratory glioma model. Neuropathology.
33:515–525. 2013.PubMed/NCBI
|
|
28
|
Breij EC, de Goeij BE, Verploegen S,
Schuurhuis DH, Amirkhosravi A, Francis J, Miller VB, Houtkamp M,
Bleeker WK, Satijn D, et al: An antibody-drug conjugate that
targets tissue factor exhibits potent therapeutic activity against
a broad range of solid tumors. Cancer Res. 74:1214–1226. 2014.
View Article : Google Scholar
|
|
29
|
Shi S, Hong H, Orbay H, Graves SA, Yang Y,
Ohman JD, Liu B, Nickles RJ, Wong HC and Cai W: ImmunoPET of tissue
factor expression in triple-negative breast cancer with a
radiolabeled antibody Fab fragment. Eur J Nucl Med Mol Imaging. Mar
24–2015.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Saito Y, Hashimoto Y, Kuroda J, Yasunaga
M, Koga Y, Takahashi A and Matsumura Y: The inhibition of
pancreatic cancer invasion-metastasis cascade in both cellular
signal and blood coagulation cascade of tissue factor by its
neutralisation antibody. Eur J Cancer. 47:2230–2239. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Matsumura Y and Maeda H: A new concept for
macromolecular therapeutics in cancer chemotherapy: Mechanism of
tumoritropic accumulation of proteins and the antitumor agent
smancs. Cancer Res. 46:6387–6392. 1986.PubMed/NCBI
|
|
32
|
Gurbaxani B, Dostalek M and Gardner I: Are
endosomal trafficking parameters better targets for improving mAb
pharmacokinetics than FcRn binding affinity? Mol Immunol.
56:660–674. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Schneider DW, Heitner T, Alicke B, Light
DR, McLean K, Satozawa N, Parry G, Yoo J, Lewis JS and Parry R: In
vivo biodistribution, PET imaging, and tumor accumulation of
86Y-and 111In-antimindin/RG-1, engineered antibody
fragments in LNCaP tumor-bearing nude mice. J Nucl Med. 50:435–443.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Adams GP, Schier R, McCall AM, Simmons HH,
Horak EM, Alpaugh RK, Marks JD and Weiner LM: High affinity
restricts the localization and tumor penetration of single-chain fv
antibody molecules. Cancer Res. 61:4750–4755. 2001.PubMed/NCBI
|
|
35
|
Olafsen T and Wu AM: Antibody vectors for
imaging. Semin Nucl Med. 40:167–181. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kampmeier F, Williams JD, Maher J, Mullen
GE and Blower PJ: Design and preclinical evaluation of a
99mTc-labelled diabody of mAb J591 for SPECT imaging of
prostate-specific membrane antigen (PSMA). EJNMMI Res. 4:132014.
View Article : Google Scholar : PubMed/NCBI
|
